JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lampen, A.
Right arrow Articles by Christians, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lampen, A.
Right arrow Articles by Christians, U.

Vol. 285, Issue 3, 1104-1112, June 1998

Metabolism and Transport of the Macrolide Immunosuppressant Sirolimus in the Small Intestine1

Alfonso Lampen, Yuanchao Zhang, Ina Hackbarth, Leslie Z. Benet, Karl-Fr. Sewing and Uwe Christians

Zentrumsabteilung für Lebensmitteltoxikologie, Tierärztliche Hochschule Hannover, Hannover, Germany (A.L.); Department of Biopharmaceutical Sciences, School of Pharmacy, University of California at San Francisco, San Francisco, California (Y.Z., L.Z.B., U.C.); Institut für Allgemeine Pharmakologie, Medizinische Hochschule Hannover, Hannover, Germany (I.H., K.-Fr.S.); and Department of Cardiothoracic Surgery, Stanford University, Stanford, California (U.C.)

Small intestinal metabolism and transport of sirolimus, a macrolide immunosuppressant with a low and highly variable oral bioavailability, were investigated using small intestinal microsomes and intestinal mucosa in the Ussing chamber. After incubation of sirolimus with human and pig small intestinal microsomes, five metabolites were detected using high performance liquid chromatography/electrospray-mass spectrometry: hydroxy, dihydroxy, trihydroxy, desmethyl and didesmethyl sirolimus. The same metabolites were generated by human liver microsomes and pig small intestinal mucosa in the Ussing chamber. Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine. Of 32 drugs tested, only known CYP3A substrates inhibited sirolimus intestinal metabolism with inhibitor constants (Ki) equal to those in human liver microsomes. The formation of hydroxy sirolimus by small intestinal microsomes isolated from 14 different patients ranged from 28 to 220 pmol·min-1·mg-1 microsomal protein. In the Ussing chamber, >99% of the sirolimus metabolites reentered the mucosa chamber against a sirolimus gradient, indicating active countertransport. Intestinal drug metabolism and countertransport into the gut lumen, drug interactions with CYP3A substrates and inhibitors in the small intestine and an 8-fold interindividual variability of the intestinal metabolite formation rate significantly contribute to the low and highly variable bioavailability of sirolimus.

0022-3565/98/2853-1104$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
J. J. Zimmerman, A. Patat, V. Parks, R. Moirand, and K. Matschke
Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Severe Hepatic Impairment
J. Clin. Pharmacol., March 1, 2008; 48(3): 285 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Picard, N. Djebli, F.-L. Sauvage, and P. Marquet
Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5
Drug Metab. Dispos., March 1, 2007; 35(3): 350 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. G. van de Kerkhof, A.-L. B. Ungell, A. K. Sjoberg, M. H. de Jager, C. Hilgendorf, I. A. M. de Graaf, and G. M. M. Groothuis
Innovative Methods to Study Human Intestinal Drug Metabolism in Vitro: Precision-Cut Slices Compared with Ussing Chamber Preparations
Drug Metab. Dispos., November 1, 2006; 34(11): 1893 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet
PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM
Drug Metab. Dispos., July 1, 2006; 34(7): 1175 - 1181.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. J. Zimmerman, K. C. Lasseter, H.-K. Lim, D. Harper, S. C. Dilzer, V. Parker, and K. Matschke
Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Mild to Moderate Hepatic Impairment
J. Clin. Pharmacol., December 1, 2005; 45(12): 1368 - 1372.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
G. W Neff, P. Ruiz, J. R Madariaga, S. Nishida, M. Montalbano, D. Meyer, D. M Levi, A. G Tzakis, and C. B O'Brien
Sirolimus-Associated Hepatotoxicity in Liver Transplantation
Ann. Pharmacother., October 1, 2004; 38(10): 1593 - 1596.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. L. Cummins, W. Jacobsen, U. Christians, and L. Z. Benet
CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 143 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. S. Pang
MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES)
Drug Metab. Dispos., December 1, 2003; 31(12): 1507 - 1519.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. J. Zimmerman, D. Harper, J. Getsy, and W. J. Jusko
Pharmacokinetic Interactions between Sirolimus and Microemulsion Cyclosporine When Orally Administered Jointly and 4 Hours Apart in Healthy Volunteers
J. Clin. Pharmacol., October 1, 2003; 43(10): 1168 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. J. A. Punt, J. Boni, U. Bruntsch, M. Peters, and C. Thielert
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
Ann. Onc., June 1, 2003; 14(6): 931 - 937.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. Matysiak-Budnik, M. Heyman, C. Candalh, D. Lethuaire, and F. Megraud
In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori
J. Antimicrob. Chemother., December 1, 2002; 50(6): 865 - 872.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. J. Wacher, J. A. Silverman, S. Wong, P. Tran-Tau, A. O. Chan, A. Chai, X.-Q. Yu, D. O'Mahony, and Z. Ramtoola
Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by D-alpha -Tocopheryl Poly(Ethylene Glycol 1000) Succinate
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 308 - 313.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. F. Paine, L. Y. Leung, H. K. Lim, K. Liao, A. Oganesian, M.-Y. Zhang, K. E. Thummel, and P. B. Watkins
Identification of a Novel Route of Extraction of Sirolimus in Human Small Intestine: Roles of Metabolism and Secretion
J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 174 - 186.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.